Godshalk Welsh Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-4,000
| Closed | -$207K | – | 122 |
|
|
2024
Q3 | $207K | Buy |
+4,000
| New | +$188K | 0.13% | 122 |
|
|
2024
Q2 | – | Sell |
-4,400
| Closed | -$239K | – | 120 |
|
|
2024
Q1 | $239K | Sell |
4,400
-1,200
| -21% | -$61.1K | 0.16% | 113 |
|
|
2023
Q4 | $287K | Hold |
5,600
| – | – | 0.21% | 105 |
|
|
2023
Q3 | $325K | Hold |
5,600
| – | – | 0.25% | 91 |
|
|
2023
Q2 | $358K | Sell |
5,600
-150
| -3% | -$10.1K | 0.25% | 97 |
|
|
2023
Q1 | $399K | Sell |
5,750
-100
| -2% | -$7.05K | 0.28% | 90 |
|
|
2022
Q4 | $421K | Sell |
5,850
-80
| -1% | -$6.03K | 0.31% | 85 |
|
|
2022
Q3 | $422K | Buy |
5,930
+380
| +7% | +$27.6K | 0.31% | 85 |
|
|
2022
Q2 | $427K | Sell |
5,550
-300
| -5% | -$22.8K | 0.31% | 84 |
|
|
2022
Q1 | $427K | Hold |
5,850
| – | – | 0.26% | 90 |
|
|
2021
Q4 | $365K | Hold |
5,850
| – | – | 0.21% | 98 |
|
|
2021
Q3 | $346K | Buy |
5,850
+250
| +4% | +$16.5K | 0.22% | 97 |
|
|
2021
Q2 | $381K | Sell |
5,600
-200
| -3% | -$13K | 0.24% | 94 |
|
|
2021
Q1 | $366K | Sell |
5,800
-200
| -3% | -$12.4K | 0.26% | 94 |
|
|
2020
Q4 | $372K | Hold |
6,000
| – | – | 0.27% | 86 |
|
|
2020
Q3 | $362K | Hold |
6,000
| – | – | 0.31% | 85 |
|
|
2020
Q2 | $353K | Hold |
6,000
| – | – | 0.33% | 83 |
|
|
2020
Q1 | $334K | Hold |
6,000
| – | – | 0.36% | 80 |
|
|
2019
Q4 | $385K | Buy |
6,000
+1,300
| +28% | +$74.5K | 0.32% | 88 |
|
|
2019
Q3 | $238K | Hold |
4,700
| – | – | 0.21% | 100 |
|
|
2019
Q2 | $213K | Hold |
4,700
| – | – | 0.2% | 102 |
|
|
2019
Q1 | $224K | Buy |
4,700
+500
| +12% | +$24.9K | 0.22% | 99 |
|
|
2018
Q4 | $218K | Buy |
4,200
+400
| +11% | +$21.5K | 0.24% | 96 |
|
|
2018
Q3 | $236K | Sell |
3,800
-150
| -4% | -$8.9K | 0.23% | 96 |
|
|
2018
Q2 | $219K | Hold |
3,950
| – | – | 0.23% | 102 |
|
|
2018
Q1 | $250K | Sell |
3,950
-150
| -4% | -$9.65K | 0.27% | 98 |
|
|
2017
Q4 | $251K | Sell |
4,100
-450
| -10% | -$28.1K | 0.25% | 106 |
|
|
2017
Q3 | $290K | Hold |
4,550
| – | – | 0.29% | 106 |
|
|
2017
Q2 | $254K | Sell |
4,550
-350
| -7% | -$19K | 0.25% | 114 |
|
|
2017
Q1 | $266K | Buy |
4,900
+650
| +15% | +$35.7K | 0.26% | 110 |
|
|
2016
Q4 | $248K | Hold |
4,250
| – | – | 0.25% | 115 |
|
|
2016
Q3 | $229K | Hold |
4,250
| – | – | 0.24% | 121 |
|
|
2016
Q2 | $313K | Hold |
4,250
| – | – | 0.33% | 102 |
|
|
2016
Q1 | $271K | Sell |
4,250
-100
| -2% | -$6.31K | 0.28% | 112 |
|
|
2015
Q4 | $299K | Sell |
4,350
-300
| -6% | -$19.8K | 0.31% | 109 |
|
|
2015
Q3 | $275K | Buy |
4,650
+300
| +7% | +$19K | 0.3% | 115 |
|
|
2015
Q2 | $289K | Sell |
4,350
-800
| -16% | -$52.7K | 0.29% | 116 |
|
|
2015
Q1 | $332K | Sell |
5,150
-200
| -4% | -$12.5K | 0.34% | 103 |
|
|
2014
Q4 | $316K | Buy |
+5,350
| New | +$302K | 0.29% | 113 |
|
Other funds holding BMY
Godshalk Welsh Capital Management's BMY Position: Q4 2024 in Review
Godshalk Welsh Capital Management sold out of Bristol-Myers Squibb (BMY) in Q4 2024, closing a stake of 4,000 shares — an estimated $207K sold.
Godshalk Welsh Capital Management first reported a position in BMY in Q4 2014 and held it in 39 quarters. The position peaked at $427K in Q2 2022. 2,487 funds tracked by Wall St. Rank hold BMY as of Q4 2024.
- Godshalk Welsh Capital Management reported no remaining Bristol-Myers Squibb position as of Q4 2024 after selling out during the quarter.
- Godshalk Welsh Capital Management sold 4,000 Bristol-Myers Squibb shares in Q4 2024, an estimated $207K.
- Godshalk Welsh Capital Management first reported a position in Bristol-Myers Squibb in Q4 2014 and held it in 39 quarters.
- Godshalk Welsh Capital Management's Bristol-Myers Squibb position peaked at $427K in Q2 2022.
- 2,487 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2024.
Based on Godshalk Welsh Capital Management's 13F filing for Q4 2024, filed 12 Feb 2025.